NDS Head of Department makes a splash in many international news sites with the published results of his 10 year ProtecT Study. A trial of 1,643 men with small prostate cancers resulted in the same 99% survival rate after a decade for those who had had surgery, radiotherapy or simply monitored the tumour.

Prof Freddie Hamdy © Academy of Medical Sciences
Professor Freddie Hamdy

Read more in the publication in the New England Journal of Medicine: http://www.nejm.org/doi/full/10.1056/NEJMoa1606220#t=article

BBC: http://www.bbc.co.uk/news/health-37362572

Guardian: https://www.theguardian.com/society/2016/sep/14/monitoring-prostate-cancer-effective-treatment

Telegraph: http://www.telegraph.co.uk/news/2016/09/14/prostate-cancer-survival-rates-equally-high-if-you-monitor-disea/

Financial Times: https://www.ft.com/content/34f1a9c8-78f7-11e6-a0c6-39e2633162d5

The Times: http://www.thetimes.co.uk/article/most-prostate-cancer-sufferers-can-avoid-pain-of-early-surgery-6rp8q8ml8

The Washington Post: https://www.washingtonpost.com/news/to-your-health/wp/2016/09/14/almost-all-men-with-early-prostate-cancer-survive-10-years-regardless-of-treatment/

New York Times online: http://www.nytimes.com/aponline/2016/09/14/health/ap-eu-med-prostate-cancer.html?_r=1 

NBC News online: http://www.nbcnews.com/health/health-news/all-prostate-cancer-treatments-about-equally-effective-study-finds-n648471

CBC online (Canada): http://www.cbc.ca/news/health/prostate-cancer-1.3762576 

Daily Telegraph Australia online: http://www.dailytelegraph.com.au/news/breaking-news/treat-or-monitor-early-prostate-cancer/news-story/9cff4fc64f9e56a5053a3103949a0ecf 

Channel NewsAsia online: http://www.channelnewsasia.com/news/world/prostate-cancer-options-show-little-difference-in-survival/3128170.html 

Further coverage

Call to watch and wait on male cancer

The Daily Mirror, 07/11/2017, p.15, Rosie Taylor

Too many men are diagnosed with prostate cancer when it will not harm them, Oxford University’s Professor Freddie Hamdy said. He argued that in many cases they should not be told they have it. He said that out of 500 diagnoses, 75% avoided treatment for three years and 44% for more than 10. He said patients “driven by anxiety” to tackle the cancer often opted for needless surgery or radiotherapy, leading to urinary and bowel problems and sexual dysfunction.

Ignore cancer call

The Sun, 07/11/2017, p.24, Unattributed


Why not treating prostate cancer ‘is best for most men’

Daily Mail, 07/11/2017, p.27, Sophie Borland & Rosie Taylor


‘Better off undiagnosed’

Daily Mail (Ireland), 07/11/2017, p.12, Katie O’Neill

Similar stories

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Results of the REF 2021: congratulations and thank you

Today, the UK funding bodies have published the results of the UK’s most recent national research assessment exercise, the Research Excellence Framework (REF) 2021.

NDS projects awarded CRUK Oxford Cancer Development Fund

Two research projects at the Nuffield Department of Surgical Sciences (NDS) have been awarded pump-prime funding from this year’s CRUK Oxford Centre Development Fund.

Blog posts

Lights, camera, action! My journey into video production

Dr Hannah McGivern provides a 'behind-the-scenes' account of her experience producing the video 'Journey of a QUOD Sample: Donating to Transplant Research', supported by the funds from the University of Oxford Public Engagement with Research (PER) Seed Fund.

Mentoring in practice

NDS has launched a new, interdepartmental mentoring scheme called RECOGNISE. In this podcast, Gemma Horbatowski (HR Advisor) interviews Monica Dolton (Programme Manager and Research Project Manager) about her experiences of mentor-mentee relationships.

Wrap up of 2021

After a brilliant year of hard work and dedication, the SITU team has done some reflection on 2021, focusing on key events, trial progression, and more. Read on to discover how the year 2021 went for the SITU team...